Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA; Charité - Universitätsmedizin Berlin, Einstein Center for Neurosciences Berlin, 10117 Berlin, Germany; Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA; Department of Clinical Neurophysiology, Hospital Universitario Rey Juan Carlos, Móstoles, Spain; Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Neurobiol Aging. 2023 Oct;130:50-60. doi: 10.1016/j.neurobiolaging.2023.05.010. Epub 2023 May 22.
Adopting preventive strategies in individuals with subclinical Alzheimer's disease (AD) has the potential to delay dementia onset and reduce healthcare costs. Thus, it is extremely important to identify inexpensive, scalable, sensitive, and specific markers to track disease progression. The electroencephalography spectral power ratio (SPR: the fast to slow spectral power ratio), a measure of the shift in power distribution from higher to lower frequencies, holds potential for aiding clinical practice. The SPR is altered in patients with AD, correlates with cognitive functions, and can be easily implemented in clinical settings. However, whether the SPR is sensitive to pathophysiological changes in the prodromal stage of AD is unclear. We explored the SPR of individuals diagnosed with amyloid-positive amnestic mild cognitive impairment (Aβ+aMCI) and its association with both cognitive function and amyloid load. The SPR was lower in Aβ+aMCI than in the cognitively unimpaired individuals and correlated with executive function scores but not with amyloid load. Hypothesis-generating analyses suggested that aMCI participants with a lower SPR had an increased probability of a positive amyloid positron emission tomography. Future research may explore the potential of this measure to classify aMCI individuals according to their AD biomarker status.
在有亚临床阿尔茨海默病（AD）的个体中采取预防策略，有可能延迟痴呆的发病并降低医疗成本。因此，识别廉价、可扩展、敏感和特异的标志物来跟踪疾病进展非常重要。脑电图频谱功率比（SPR：快到慢的频谱功率比），衡量功率分布从高频到低频的转移，具有辅助临床实践的潜力。AD 患者的 SPR 发生改变，与认知功能相关，并且可以在临床环境中轻松实施。然而，SPR 是否对 AD 前驱期的病理生理变化敏感尚不清楚。我们研究了被诊断为淀粉样蛋白阳性遗忘性轻度认知障碍（Aβ+aMCI）的个体的 SPR，及其与认知功能和淀粉样蛋白负荷的关系。与认知正常的个体相比，Aβ+aMCI 个体的 SPR 较低，与执行功能评分相关，但与淀粉样蛋白负荷无关。假设生成分析表明，SPR 较低的 aMCI 参与者进行正电子发射断层扫描（PET）检查有更高的淀粉样蛋白阳性概率。未来的研究可能会探索这种测量方法在根据 AD 生物标志物状态对 aMCI 个体进行分类方面的潜力。
